Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06954753

Predicting Cancer in Pancreatic Cystic Lesions Through Artificial Intelligence

This international, multicenter retrospective study aims to develop a deep learning (DL)-based predictive model to identify malignant transformation in pancreatic cystic lesions, improving upon current clinical guidelines. The model will integrate clinical, biochemical, and multimodal imaging data. Several 3D convolutional neural networks will be trained using advanced preprocessing, data augmentation, and hybrid fusion techniques. Model performance will be compared to that of existing international guidelines. The study involves no additional procedures for patients and adheres to strict data anonymization and privacy regulations.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients diagnosed with PCL(s ) who underwent pancreatic surgery in one of the participant centers. Surgical indication must adhere to at least one of current guidelines on PCLs management (6), based on clinical, biochemical, and radiological (MR and/or EUS) features.
  • Pancreatic surgery B83performed for supposed increased risk of cyst(s) malignant degeneration following current guidelines on PCLs management (6).
  • Absence of clinical, biochemical, radiological, and anatomopathological evidence of pancreatic cancer at pancreatic surgery.
  • Non-opposition to the anonymous data processing by the included patients.

Exclusion criteria

  • Patients presenting with evidence of pancreatic cancer at surgery.
  • PCL(s) diagnosis and treatment performed without one between EUS and pancreatic MR. surgery performed in the absence of the criteria proposed by current guidelines.
  • Unavailability of both preoperative EUS and pancreatic MR data.
  • Unavailability of postoperative PCL(s) anatomopathological analysis results.
  • SBO diagnosis performed without CT-scan.

Treatment and study plan

Pancreatic surgery

Procedure

Pancreatic resective surgery performed for pancreatic cystic lesions with high risk of malignant degeneration based on clinical, biochemical, and/or radiological features following current guidelines on pancreatic cystic lesions management.

Primary outcomes

  1. Prediction of malignant degeneration of pancreatic cystics lesions

    Time frame: 90 days from patients hospital discharge.

    Predict the presence of malignant degeneration (defined as: high grade dysplasia, in situ PADC, or T1 PADC) in pancreatic cystic lesion(s) using artificial intelligence model based on clinical, biochemical, and radiological features. This will be measured through Area Under the Receiver Operator Characteristic curve (AUROC) assesment. AUROC varies between 0.5 and 1, corresponding to no class separation capacity and full class separation capacity, respectively.

Secondary outcomes

  1. Accuracy of performance evaluation

    Time frame: 90 days from patients hospital discharge.

    the number of true positives and true negatives among all predictions. It varies between 0 (no correct prediction) to 1 (full correct predictions).

  2. Precision of performance evaluation

    Time frame: 90 days from patients hospital discharge.

    The number of true positives divided by all the positive predictions (true positives and false positives). It varies between 0 (no correct prediction) to 1 (full correct predictions).

  3. Recall of performance evaluation

    Time frame: 90 days from patients hospital discharge.

    The number of true positives divided by the actual positive instances in the dataset (true positives and false negatives). It varies between 0 (no correct prediction) to 1 (full correct predictions).

  4. Balanced accuracy

    Time frame: 90 days from patients hospital discharge.

    the aritmethic mean of sensitivity and specificity. It varies between 0 (no correct prediction) to 1 (full correct predictions).

  5. F1-score

    Time frame: 90 days from patients hospital discharge.

    It combines precision and recall. It ranges from 0-100%, and a higher F1 score denotes a better quality classifier.

  6. Confusion matrix

    Time frame: 90 days from patients hospital discharge.

    A visual representation of true positives, false positives, true negatives, and false negatives. It is depicted through a table.

  7. Log-loss

    Time frame: 90 days from patients hospital discharge.

    It indicates how close the prediction probability is to the corresponding actual/true value (0 or 1 in case of binary classification). The more the predicted probability diverges from the actual value, the higher is the log-loss value.

  8. Cohen's Kappa

    Time frame: 90 days from patients hospital discharge.

    A metric used to measure the level of agreement between two raters which can be a useful tool to gauge the performance of a classification model. It accounts for the fact that the raters may happen to agree on some items purely by chance. It varies between 0 (no correct prediction) to 1 (full correct predictions).

Study contacts

Contact information is provided by the study sponsor or research team.

Andrea CHIERICI

CONTACT

[email protected]

+33 0634799833

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nice

Other

Registry information

Official study title

Deep Learning for Malignant Degeneration Prediction of Pancreatic Cystic Lesions - Beyond High-risk Stigmata

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
May 2, 2025
Registry last updated
May 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.